Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); programmed cell death 1 (PD-1; PDCD1; CD279)


INDICATION: Pancreatic cancer

Patient sample and mouse studies suggest inhibiting CXCR2 could help treat pancreatic ductal adenocarcinoma (PDAC). In patient samples, high levels of CXCR2 in neutrophils at the tumor borders

Read the full 309 word article

User Sign In